Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance

Journal of Pharmaceutical and Biomedical Analysis

Volumn 48, Issue 5, 2008, Pages 1430-1440

  Chitturi, Sreenivasa Rao ^a   Bharathi, Ch ^a   Reddy, A V Raghava ^a   Reddy, K Chandrasekhar ^a   Sharma, Hemant Kumar ^a   Handa, Vijay Kumar ^a   Dandala, Ramesh ^a   Bindu, V Hima ^b  

^a APL Research Centre   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Characterization; Gradient RP HPLC; Lopinavir; Method development and validation; Related substances

Indexed keywords

LOPINAVIR;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG IMPURITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; GUIDELINES AS TOPIC; HIV PROTEASE INHIBITORS; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHARMACEUTICAL PREPARATIONS; PHOSPHATES; POTASSIUM COMPOUNDS; PYRIMIDINONES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; TIME FACTORS; WATER;

EID: 58249110561     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.09.015     Document Type: Article

References (25)

1. Raffanti S., and Haas D.W. Goodman and Gilman's: The Pharmacological Basis of 422 Therapeutics. McGraw-Hill (2001) 1371-1372
2. Sham H.L., Kempf D.J., Molla A., Marsh K.C., Kumar G.N., Chen C.M., Kati W., Stewart K., Lal R., Hsu A., Betebenner D., Korneyeva M., Vasavanonda S., McDonald E., Saldivar A., Wideburg N., Chen X., Niu P., Park C., Jayanti V., Grabowski B., Granneman G.R., Sun E., Japour A.J., Leonard J.M., Plattner J.J., and Norbeck D.W. Antimicrob. Agents Chemother. 42 (1998) 3218-3224
3. Kumar G.N., Jayanti V., Lee R.D., Whittern D.N., Uchic J., Thomas S., Johnson P., Grabowski B., Sham H., Betebenner D., Kempf D.J., and Denissen J.F. Drug Metab. Dispos. 27 (1999) 86-91
4. Notari S., Bocedi A., Ippolito G., Narciso P., Pucillo L.P., Tossini G., Donnorso R.P., Gasparrini F., Ascenzi P., and Barcelo D. J. Chromatogr. B 831 (2006) 258-266
5. Hirabayashi Y., Tsuchiya K., Kimura S., and Oka S. Biomed. Chromatogr. 20 (2006) 28-36
6. Poirier J.M., Robidou P., and Jaillon P. Ther. Drug Monit. 27 (2005) 186-192
7. Dailly E., Raffi F., and Jolliet P. J. Chromatogr. B 813 (2004) 353-358
8. Rezk N.L., Tidwell R.R., and Kashuba A.D.M. J. Chromatogr. B 805 (2004) 241-247
9. Faux J., Venisse N., le Moal G., Dupuis A., and Bouquet S. Chromatographia 57 (2003) 421-426
10. Turner M.L., Reed-Walker K., King J.R., and Acosta E.P. J. Chromatogr. B 784 (2003) 331-341
11. Justesen U.S., Pedersen C., and Klitgaard N.A. J. Chromatogr. B 783 (2003) 491-500
12. Usami Y., Oki T., Nakai M., Sagisaka M., and Kaneda T. Chem. Pharm. Bull. 51 (2003) 715-718
13. Ray J., Pang E., and Carey D. J. Chromatogr. B 775 (2002) 225-230
14. Marzolini C., Beguin A., Telenti A., Schreyer A., Buclin T., Biollaz J., and Decosterd L.A. J. Chromatogr. B 774 (2002) 127-140
15. Titier K., Lagrange F., Pehourcq F., Edno-Mcheik L., Moore N., and Molimard M. Ther. Drug Monit. 24 (2002) 417-424
16. Tribut O., Arvieux C., Michelet C., Chapplain J.M., Allain H., and Bentue-Ferrer D. Ther. Drug Monit. 24 (2002) 554-562
17. Leibenguth P., Le Guellec C., Besnier J.M., Bastides F., Mace M., Gaudet M.L., Autret-Leca E., and Paintaud G. Ther. Drug Monit. 23 (2001) 679-688
18. Faux J., Venisse N., Olivier J.C., and Bouquet S. Chromatographia 54 (2001) 469-473
19. Donato E.M., Dias C.L., Rossi R.C., Valente R.S., Froelich P.E., and Bergold A.M. Chromatographia 63 (2006) 437-443
20. Seshachalam U., Haribabu B., and Chandrasekhar K.B. Biomed. Chromatogr. 21 (2007) 716-723
21. ICH Guideline Q3A(R2), Impurities in New Drug Substances, October 25, 2006.
22. ICH Guideline Q7A, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, November 2005.
23. Stoner E.J., Cooper A.J., Dickman D.A., Kolaczkowski L., Lallaman J.E., Liu J.-H., Oliver-Shaffer P.A., Patel K.M., Paterson Jr. J.B., Plata D.J., Riley D.A., Sham H.L., Stengel P.J., and Tien J.-H.J. Org. Process Res. Dev. 4 (2000) 264-269
24. Snyder L.R., Kirkland J.J., and Glajch J.L. Practical HPLC Method Development (March 1997)
25. ICH Guideline, Q2(R1), Validation of Analytical Procedures, Text and Methodology, November 2005.